OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2
” NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 ” ” First regulatory filing for fruquintinib for use in...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:‹HCM; HKEX:‹13) today announces that data from FRUTIGA,...
HUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong
HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:‹HCM, HKEX:‹13) (œHUTCHMED) today announces that it has completed enrollment of...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (œHUTCHMED) (Nasdaq/AIM:‹HCM, HKEX:‹13) today announces that under the 2023 simple...
FRUZAQLA™ (fruquintinib) Now Available from Onco360
Fruquintinib Becomes First Antineoplastic Drug to Be Prescribed in US
Takeda`s colorectal cancer drug Fruzaqla cleared by FDA
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:‹HCM; HKEX:‹13) today announces that the Center for Drug...